Key clinical point: Patient-reported outcomes support pembrolizumab plus chemotherapy for first-line treatment of metastatic non–small cell lung cancer.
Major finding: At week 18, a higher percentage of patients in the pembrolizumab plus chemotherapy group reported improvements in health-related quality of life, compared with patients in the placebo plus chemotherapy group (36.2% . 27.7%).
Study details: An analysis of patient-reported outcomes in the phase 3 KEYNOTE-407 trial.
Disclosures: The study was funded by Merck. The investigators reported additional relationships with Novartis, Genentech, Pfizer, and others.
Mazieres J et al. J Clin Oncol. 2019 Nov 21. doi: 10.1200/JCO.19.01348.